SGLT2 inhibitors may delay disease progression in patients with prostate cancer receiving hormone therapy, suggesting their potential role as adjuncts to hormonal therapy in the treatment of prostate cancer. The gene discussed is SLC5A2; the disease is prostate carcinoma.